The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-
mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms …
mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms …
YB‐1 protein: functions and regulation
DN Lyabin, IA Eliseeva… - Wiley Interdisciplinary …, 2014 - Wiley Online Library
The Y‐box binding protein 1 (YB‐1, YBX1) is a member of the family of DNA‐and RNA‐
binding proteins with an evolutionarily ancient and conserved cold shock domain. It falls into …
binding proteins with an evolutionarily ancient and conserved cold shock domain. It falls into …
LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1α pathway
F Xu, M Huang, Q Chen, Y Niu, Y Hu, P Hu, D Chen… - Cancer research, 2021 - AACR
Gemcitabine (GEM) resistance is a major challenge for chemotherapy of pancreatic cancer.
Previous studies have reported on the role of long noncoding RNA (lncRNA) in …
Previous studies have reported on the role of long noncoding RNA (lncRNA) in …
The translational landscape of mTOR signalling steers cancer initiation and metastasis
AC Hsieh, Y Liu, MP Edlind, NT Ingolia, MR Janes… - Nature, 2012 - nature.com
The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein
synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream …
synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream …
Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation
J Yu, W Li, G Hou, D Sun, Y Yang, S Yuan… - … & Molecular Medicine, 2023 - nature.com
Hepatitis B protein x (HBx) has been reported to promote tumorigenesis in hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC), but the mechanism awaits further …
(HBV)-related hepatocellular carcinoma (HCC), but the mechanism awaits further …
Y-box-binding protein 1 (YB-1) and its functions
IA Eliseeva, ER Kim, SG Guryanov… - Biochemistry …, 2011 - Springer
This review describes the structure and functions of Y-box binding protein 1 (YB-1) and its
homologs. Interactions of YB-1 with DNA, mRNAs, and proteins are considered. Data on the …
homologs. Interactions of YB-1 with DNA, mRNAs, and proteins are considered. Data on the …
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition
V Evdokimova, C Tognon, T Ng, P Ruzanov, N Melnyk… - Cancer cell, 2009 - cell.com
Increased expression of the transcription/translation regulatory protein Y-box binding protein-
1 (YB-1) is associated with cancer aggressiveness, particularly in breast carcinoma. Here …
1 (YB-1) is associated with cancer aggressiveness, particularly in breast carcinoma. Here …
Cold shock proteins: from cellular mechanisms to pathophysiology and disease
JA Lindquist, PR Mertens - Cell Communication and Signaling, 2018 - Springer
Cold shock proteins are multifunctional RNA/DNA binding proteins, characterized by the
presence of one or more cold shock domains. In humans, the best characterized members of …
presence of one or more cold shock domains. In humans, the best characterized members of …
Long noncoding RNA HULC modulates the phosphorylation of YB‐1 through serving as a scaffold of extracellular signal–regulated kinase and YB‐1 to enhance …
D Li, X Liu, J Zhou, J Hu, D Zhang, J Liu, Y Qiao… - …, 2017 - Wiley Online Library
Dysregulated expression of long noncoding RNAs has been reported in many types of
cancers, indicating that it may play a critical role in tumorigenesis. The long noncoding RNA …
cancers, indicating that it may play a critical role in tumorigenesis. The long noncoding RNA …
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival
JH Law, G Habibi, K Hu, H Masoudi, MYC Wang… - Cancer research, 2008 - AACR
Drugs that target the insulin-like growth factor-I receptor (IGF-IR) and/or insulin receptor (IR)
are currently under investigation for a variety of malignancies including breast cancer …
are currently under investigation for a variety of malignancies including breast cancer …